Back to Search
Start Over
Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study.
- Source :
-
The American journal of cardiology [Am J Cardiol] 2013 Feb 01; Vol. 111 (3), pp. 352-5. Date of Electronic Publication: 2012 Nov 17. - Publication Year :
- 2013
-
Abstract
- Although the effect of niacin on the glucose levels in subjects with diabetes mellitus has been investigated, niacin's effects on the glucose levels and atherosclerosis in subjects with normal glucose levels have not been well established. We examined the effect of niacin on the glucose levels, coronary stenosis progression using quantitative coronary angiography, and clinical events in 407 subjects who had a baseline glucose level <100 mg/dl and were enrolled in the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), or Carotid Plaque Composition by MRI during lipid-lowering (CPC) study testing active niacin therapy. Although the fasting glucose levels increased significantly within 3 years in both subjects treated with niacin (from 85.6 ± 9.5 to 95.5 ± 19.7 mg/dl, p <0.001) and without niacin (from 85.2 ± 9.6 to 90 ± 17.9 mg/dl, p = 0.009), those treated with niacin had a significantly larger increase in glucose levels than those not taking niacin (9.88 vs 4.05 mg/dl, p = 0.002). Overall, 29% of subjects developed impaired fasting glucose within 3 years. Incident impaired fasting glucose was significantly more likely to be observed in subjects treated with niacin than in those who were not. However, the frequency of new-onset diabetes mellitus did not differ significantly between the 2 groups (5.6% vs 4.8%, p = 0.5). Niacin-treated subjects compared to untreated subjects had significantly less change in mean coronary stenosis (0.1 ± 0.3% vs 2 ± 12%, p <0.0001) and less major cardiovascular events (8% vs 21%, p = 0.001). In conclusion, the use of niacin for 3 years in subjects with normal baseline glucose levels was associated with an increase in blood glucose levels and the risk of developing impaired fasting glucose, but not diabetes mellitus, and was associated with a significantly reduced incidence of coronary stenosis progression and major cardiovascular events.<br /> (Copyright © 2013 Elsevier Inc. All rights reserved.)
- Subjects :
- Carotid Stenosis blood
Carotid Stenosis complications
Cholesterol, HDL blood
Cholesterol, LDL blood
Coronary Angiography
Coronary Stenosis diagnosis
Coronary Stenosis etiology
Disease Progression
Female
Follow-Up Studies
Humans
Male
Middle Aged
Niacin therapeutic use
Plaque, Atherosclerotic blood
Plaque, Atherosclerotic complications
Treatment Outcome
Blood Glucose metabolism
Carotid Stenosis drug therapy
Coronary Stenosis drug therapy
Hypolipidemic Agents therapeutic use
Lipids blood
Magnetic Resonance Imaging methods
Plaque, Atherosclerotic drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1879-1913
- Volume :
- 111
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- The American journal of cardiology
- Publication Type :
- Academic Journal
- Accession number :
- 23168285
- Full Text :
- https://doi.org/10.1016/j.amjcard.2012.09.034